Pursue either isoform-specific RGS6 engineering or pharmacologic RGS6 activation to enhance protective signaling. The debate strongly argues these are premature because core isoform biology, target engagement, selectivity, and safety are not established.
Curated pathway from expert analysis
flowchart TD
A["RGS6 Expression<br/>G Protein Signaling Regulator"]
B["GIRK Channel<br/>Regulation"]
C["Dopamine Signaling<br/>Modulation"]
D["Neural Excitability<br/>Control"]
E["RGS6 as<br/>Neural Circuit Target"]
F["RGS6-Based<br/>Therapeutic Modulation"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for RGS6 yet. Search RCSB →
Median TPM across 13 brain regions for RGS6 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for RGS6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF WT rats receive daily intraperitoneal injections of a selective small-molecule RGS6 activator (BT-11, 10 mg/kg) starting 1 week before and continuing 4 weeks after 6-OHDA medial forebrain bundle le | ≥40% reduction in net ipsilateral rotations; ≥30% increase in striatal tissue dopamine via HPLC-EC | — no observation — | pending | 0.28 |
| IF neuron-specific RGS6 is genetically overexpressed in C57BL/6 mice prior to chronic MPTP administration (40 mg/kg cumulative over 5 days), THEN motor performance on accelerating rotarod will improve | ≥25% improvement in rotarod latency; ≥35% increase in stereological TH+ neuron count in substantia nigra pars compacta | — no observation — | pending | 0.35 |